• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评价 BiOSS LIM C 支架与 Orsiro 支架在猪冠状动脉模型中的血管反应。

Assessment of vascular response to BiOSS LIM C stents vs Orsiro stents in the porcine coronary artery model.

机构信息

Department of Invasive Cardiology, Central Clinical Hospital of the Ministry of Interior and Administration, Warsaw, Poland.

Mossakowski Research Science Center, Polish Academy of Science, Warsaw, Poland.

出版信息

Cardiovasc Ther. 2017 Aug;35(4). doi: 10.1111/1755-5922.12267.

DOI:10.1111/1755-5922.12267
PMID:28423237
Abstract

AIMS

The optimal treatment strategy for coronary bifurcation lesions is still unknown. The aim of the study was to assess applicability of the new cobalt-chromium version of the sirolimus-eluting dedicated bifurcation BiOSS LIM C stent in comparison with regular sirolimus-eluting Orsiro  stent in a porcine coronary model.

METHODS

A total of 13 BiOSS LIM C stents and 6 Orsiro stents were implanted in normal nonatherosclerotic porcine straight coronary arteries of six animals using 1.2:1.0 stent-to-artery ratio. Stent geometry and morphology were evaluated by Faxitron imaging. Vascular response was assessed by quantitative coronary angiography (QCA), optical coherence tomography (OCT), and histological analyses.

RESULTS

OCT performed at 28 days confirmed that all stents were patent with no signs of thrombus. In morphometric analysis, no differences between groups regarding stent diameter (P=.141), neointima area (P=.247), % area stenosis (P=.293), or % diameter stenosis (P=.069) were observed. Also, no significant differences were noted between groups regarding their histopathology scores. The injury and inflammation scores were low (mean grade<1) in all groups.

CONCLUSIONS

The novel BiOSS LIM C stent demonstrates good short-term vascular effects in a porcine coronary bifurcation model which are comparable with Orsiro stents.

摘要

目的

冠状动脉分叉病变的最佳治疗策略仍不清楚。本研究旨在评估新型钴铬版西罗莫司洗脱专用分叉 BiOSS LIM C 支架在猪冠状动脉模型中与常规西罗莫司洗脱 Orsiro 支架相比的适用性。

方法

在 6 只动物的正常非动脉粥样硬化猪直冠状动脉中,以 1.2:1.0 的支架-动脉比,使用 13 个 BiOSS LIM C 支架和 6 个 Orsiro 支架进行植入。采用 Faxitron 成像评估支架的几何形状和形态。通过定量冠状动脉造影(QCA)、光学相干断层扫描(OCT)和组织学分析评估血管反应。

结果

28 天时进行的 OCT 检查证实所有支架均通畅,无血栓迹象。在形态计量学分析中,两组支架直径(P=.141)、新生内膜面积(P=.247)、%面积狭窄(P=.293)或%直径狭窄(P=.069)均无差异。此外,两组的组织病理学评分也无显著差异。所有组的损伤和炎症评分均较低(平均等级<1)。

结论

新型 BiOSS LIM C 支架在猪冠状动脉分叉模型中显示出良好的短期血管效果,与 Orsiro 支架相当。

相似文献

1
Assessment of vascular response to BiOSS LIM C stents vs Orsiro stents in the porcine coronary artery model.评价 BiOSS LIM C 支架与 Orsiro 支架在猪冠状动脉模型中的血管反应。
Cardiovasc Ther. 2017 Aug;35(4). doi: 10.1111/1755-5922.12267.
2
Bifurcation Optimisation Stent System (BiOSS Lim) with sirolimus elution: results from porcine coronary artery model.带有雷帕霉素洗脱的分叉优化支架系统(BiOSS Lim):来自猪冠状动脉模型的结果。
EuroIntervention. 2011 Sep;7(5):614-20. doi: 10.4244/EIJV7I5A98.
3
Comparative assessment of three drug eluting stents with different platforms but with the same biodegradable polymer and the drug based on quantitative coronary angiography and optical coherence tomography at 12-month follow-up.在12个月随访时,基于定量冠状动脉造影和光学相干断层扫描,对三种具有不同平台但使用相同可生物降解聚合物和药物的药物洗脱支架进行比较评估。
Int J Cardiovasc Imaging. 2018 Mar;34(3):353-365. doi: 10.1007/s10554-017-1251-7. Epub 2017 Sep 30.
4
12-month intravascular ultrasound observations from BiOSS® first-in-man studies.来自BiOSS®人体首次研究的12个月血管内超声观察结果。
Int J Cardiovasc Imaging. 2016 Sep;32(9):1339-1347. doi: 10.1007/s10554-016-0926-9. Epub 2016 Jun 17.
5
Regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIM® stent: the randomised, multicentre, open-label, controlled POLBOS II trial.普通药物洗脱支架与专用冠状动脉分叉西罗莫司洗脱BiOSS LIM®支架对比:随机、多中心、开放标签、对照的POLBOS II试验
EuroIntervention. 2016 Dec 10;12(11):e1404-e1412. doi: 10.4244/EIJY15M11_11.
6
First-in-man study of dedicated bifurcation cobalt-chromium sirolimus-eluting stent BiOSS LIM C® - three-month results.首例专用分叉钴铬依维莫司洗脱支架 BiOSS LIM C® 的人体研究 - 三个月结果。
Kardiol Pol. 2018;76(2):464-470. doi: 10.5603/KP.a2017.0226. Epub 2017 Dec 1.
7
BiOSS LIM C: thin-strut cobalt-chromium version of the dedicated bifurcation stent.BiOSS LIM C:专用分叉支架的薄壁钴铬版本。
Expert Rev Med Devices. 2017 Apr;14(4):279-284. doi: 10.1080/17434440.2017.1318058. Epub 2017 Apr 19.
8
First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).首例人体生物可吸收聚合物涂层依维莫司洗脱支架的评估:DESOLVE I 试验(载有依维莫司和生物可吸收聚合物的 DES 治疗原发性冠状动脉病变患者)的影像学和临床结果。
JACC Cardiovasc Interv. 2013 Oct;6(10):1026-34. doi: 10.1016/j.jcin.2013.05.013. Epub 2013 Sep 18.
9
Treatment with a dedicated bifurcation sirolimus-eluting cobalt-chromium stent for distal left main coronary artery disease: rationale and design of the POLBOS LM study.专用分叉西罗莫司洗脱钴铬支架治疗左主干冠状动脉远端病变的研究(POLBOS LM 研究):理论基础和设计。
EuroIntervention. 2020 Oct 23;16(8):654-662. doi: 10.4244/EIJ-D-19-00361.
10
Vascular response and mechanical integrity of the new biodegradable polymer coated sirolimus-eluting PROLIM stent implanted in porcine coronary arteries.新型可生物降解聚合物涂层西罗莫司洗脱 PROLIM 支架在猪冠状动脉中的血管反应和机械完整性。
Kardiol Pol. 2012;70(7):703-11.

引用本文的文献

1
The Randomized, Multicenter, Open-Label, Controlled POLBOS 3 Trial Comparing Regular Drug-Eluting Stents and the Sirolimus-Eluting BiOSS LIM C Dedicated Coronary Bifurcation Stent: Four-Year Results.比较普通药物洗脱支架与西罗莫司洗脱BiOSS LIM C专用冠状动脉分叉支架的随机、多中心、开放标签、对照POLBOS 3试验:四年结果
Biomedicines. 2024 Apr 23;12(5):938. doi: 10.3390/biomedicines12050938.
2
Twelve-month clinical results from the new cobalt-chromium sirolimus-eluting dedicated bifurcation stent BiOSS LIM C Registry.新型钴铬西罗莫司洗脱专用分叉支架BiOSS LIM C注册研究的12个月临床结果。
Arch Med Sci. 2020 Feb 10;19(2):324-330. doi: 10.5114/aoms.2020.92974. eCollection 2023.
3
Angiographic Restenosis in Coronary Bifurcations Treatment with Regular Drug Eluting Stents and Dedicated Bifurcation Drug-Eluting BiOSS Stents: Analysis Based on Randomized POLBOS I and POLBOS II Studies.
冠状动脉分叉病变应用常规药物洗脱支架和专用分叉药物洗脱 BiOSS 支架治疗后的血管造影再狭窄:基于随机 POLBOS I 和 POLBOS II 研究的分析。
Cardiovasc Ther. 2020 Jan 21;2020:6760205. doi: 10.1155/2020/6760205. eCollection 2020.
4
Rationale and design of the randomized, multicenter, open-label, controlled POLBOS 3 trial aimed to compare regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIM C stent.随机、多中心、开放标签、对照的POLBOS 3试验的原理与设计,旨在比较普通药物洗脱支架与专用冠状动脉分叉处西罗莫司洗脱BiOSS LIM C支架。
Medicine (Baltimore). 2019 Apr;98(14):e15106. doi: 10.1097/MD.0000000000015106.
5
Mehran in-stent restenosis classification adapted for coronary bifurcations: the impact on 4-year follow-up from randomized clinical studies POLBOS I and II.适用于冠状动脉分叉病变的梅兰支架内再狭窄分类:来自随机临床研究POLBOS I和II的4年随访结果影响
Postepy Kardiol Interwencyjnej. 2018;14(3):299-303. doi: 10.5114/aic.2018.78335. Epub 2018 Sep 21.